Introduction: The introduction of biological therapies has revolutionized the treatmentof moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor of interleukin17A, has shown great results in terms of effcacyand safety in both clinical trials and real-worldexperiences. However, there is a lack of longterm real-world data available for ixekizumab.Methods: We conducted a multicenter real-lifestudy to evaluate the effectiveness and safety ofixekizumab in patients with moderate-to-severeplaque psoriasis. Psoriasis Area and SeverityIndex score (PASI) was collected at baseline andafter 1, 2, 3, 4, and 5 years. The occurrence ofany adverse events was recorded at each timepoint.
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis)
Orsini D;
2024-01-01
Abstract
Introduction: The introduction of biological therapies has revolutionized the treatmentof moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor of interleukin17A, has shown great results in terms of effcacyand safety in both clinical trials and real-worldexperiences. However, there is a lack of longterm real-world data available for ixekizumab.Methods: We conducted a multicenter real-lifestudy to evaluate the effectiveness and safety ofixekizumab in patients with moderate-to-severeplaque psoriasis. Psoriasis Area and SeverityIndex score (PASI) was collected at baseline andafter 1, 2, 3, 4, and 5 years. The occurrence ofany adverse events was recorded at each timepoint.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
